Lessons from the United Kingdom's COVID-19 vaccination strategy

Summary: The AZD1222 vaccine has been approved for emergency use in the UK with an interval of 4-12 weeks between doses. Analysis shows that the vaccine is efficacious with two doses and provides immunoprotection after the first dose before the second dose is administered.

Summary: After vaccination with ChAdOx1 nCov-19, rare immune thrombotic thrombocytopenia can occur due to platelet-activating antibodies against PF4, resulting in various thrombotic events. Most patients in this case series were women, with fatal outcomes such as cerebral venous thrombosis and intracranial hemorrhage. Additional studies are needed to further investigate and understand this phenomenon.